Xspray Pharma publishes its annual report for 2021
Regulatory press release 2022-03-25
“In 2021, we once again confirmed that Xspray Pharma’s unique technology platform can produce amorphous versions of protein kinase inhibitors. Having our processes in place means that we can shorten the development time for new products. I look forward to an intensive and productive 2022, during which Xspray Pharma’s organization will develop and mature, and to the growth of our pipeline. In parallel to this, the commercial preparations are well underway, as is the FDA’s review process of our first product candidate.
We have learned a lot during the past year, and consequently we took a strategically important decision to focus on improved pharmaceuticals. This is a decision that simplifies and streamlines our operations. Focus will be on identification and development of product candidates where our unique technology can be used to achieve improved pharmaceuticals”, said Per Andersson, CEO of Xspray Pharma.
The annual report is attached, and can also be downloaded from the company's website, www.xspraypharma.com.